The estimated Net Worth of Mary M. Rozenman is at least $55 millier dollars as of 1 March 2018. Mary Rozenman owns over 1,807 units of Aimmune Therapeutics Inc stock worth over $54,982 and over the last 9 years Mary sold AIMT stock worth over $0.
Sign up
Mary Rozenman AIMT stock SEC Form 4 insiders trading
Mary has made over 10 trades of the Aimmune Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Mary exercised 1,807 units of AIMT stock worth $5,457 on 1 March 2018.
The largest trade Mary's ever made was exercising 75,010 units of Aimmune Therapeutics Inc stock on 26 December 2017 worth over $226,530. On average, Mary trades about 16,194 units every 34 days since 2016. As of 1 March 2018 Mary still owns at least 1,936 units of Aimmune Therapeutics Inc stock.
You can see the complete history of Mary Rozenman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Mary Rozenman's mailing address?
Mary's mailing address filed with the SEC is 8000 Marina Blvd #200, Brisbane, CA 94005, USA.
Insiders trading at Aimmune Therapeutics Inc
Over the last 9 years, insiders at Aimmune Therapeutics Inc have traded over $19,285,948 worth of Aimmune Therapeutics Inc stock and bought 61,698,079 units worth $2,225,231,200 . The most active insiders traders include Des Produits Nestle S.A. So..., Patrick G Enright et Des Produits Nestle S.A.Nes.... On average, Aimmune Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $21,038,606. The most recent stock trade was executed by Des Produits Nestle S.A. So... on 13 October 2020, trading 54,117,287 units of AIMT stock currently worth $1,867,046,402.
What does Aimmune Therapeutics Inc's logo look like?
Complete history of Mary Rozenman stock trades at Aimmune Therapeutics Inc
Aimmune Therapeutics Inc executives and stock owners
Aimmune Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Stacey Denenberg Seltzer,
Director -
Jeffrey H Knapp,
Chief Operating Officer -
Susan E. Barrowcliffe,
General Manager, Europe -
Capital Partners Ii, Llc Ta...,
-
Kathryn E Falberg,
Director -
Daniel C Md Adelman,
Chief Medical Officer -
Mary M. Rozenman,
See Remarks -
Capital Management Ii, Llc ...,
-
Capital Partners Ii, Llc Lo...,
-
Gregory Behar,
Director -
Douglas T. Sheehy,
See Remarks -
Mark T Iwicki,
Director -
Eric Bjerkholt,
Chief Financial Officer -
Mark Mcdade,
Director -
Warren L. De Souza,
Chief Financial Officer -
Robert Myles Elfont,
Chief Medical Officer -
Jayson Donald Alexander Dallas,
President and CEO -
Health Science Us Holdings,...,
-
Des Produits Nestle S.A.Nes...,
-
Bakker Juliet Tammenoms,
10% owner -
Stephen George Dilly,
See Remarks -
Andrew Oxtoby,
Chief Commercial Officer -
Capital Partners Ii, Llc Ta...,
-
Patrick G Enright,
Director -
Brett K Haumann,
Director -
Des Produits Nestle S.A. So...,
10% owner